DE602004029393D1 - Tgf-beta1-bindende und geträgerte peptide - Google Patents

Tgf-beta1-bindende und geträgerte peptide

Info

Publication number
DE602004029393D1
DE602004029393D1 DE602004029393T DE602004029393T DE602004029393D1 DE 602004029393 D1 DE602004029393 D1 DE 602004029393D1 DE 602004029393 T DE602004029393 T DE 602004029393T DE 602004029393 T DE602004029393 T DE 602004029393T DE 602004029393 D1 DE602004029393 D1 DE 602004029393D1
Authority
DE
Germany
Prior art keywords
peptides
supported
tgf
preferred embodiments
supported peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004029393T
Other languages
English (en)
Inventor
Anthony G Day
David A Estell
Christopher J Murray
Scott D Power
Beverly R Turnquest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Danisco US Inc
Original Assignee
Danisco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco US Inc filed Critical Danisco US Inc
Publication of DE602004029393D1 publication Critical patent/DE602004029393D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
DE602004029393T 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide Active DE602004029393D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51815403P 2003-11-06 2003-11-06
US52040303P 2003-11-13 2003-11-13
US53120703P 2003-12-19 2003-12-19
US53118903P 2003-12-19 2003-12-19
US53095403P 2003-12-19 2003-12-19
PCT/US2004/036979 WO2005046710A2 (en) 2003-11-06 2004-11-06 Tgf-beta binding and supported peptides

Publications (1)

Publication Number Publication Date
DE602004029393D1 true DE602004029393D1 (de) 2010-11-11

Family

ID=34596198

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004029393T Active DE602004029393D1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide
DE602004029812T Active DE602004029812D1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004029812T Active DE602004029812D1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide

Country Status (9)

Country Link
US (8) US20080113917A1 (de)
EP (4) EP1692160B1 (de)
JP (2) JP4843497B2 (de)
AT (4) ATE486087T1 (de)
CA (1) CA2544820C (de)
DE (2) DE602004029393D1 (de)
DK (2) DK1692158T3 (de)
ES (1) ES2375360T3 (de)
WO (4) WO2005046709A2 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486087T1 (de) * 2003-11-06 2010-11-15 Danisco Us Inc Fgf-5-bindende und geträgerte peptide
AU2006246425B2 (en) * 2003-11-06 2012-03-22 Genencor International, Inc. Personal care compositions and methods for their use
WO2005047302A1 (en) * 2003-11-06 2005-05-26 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
JP5255841B2 (ja) * 2004-10-15 2013-08-07 ジェネンコー・インターナショナル・インク 競合示差スクリーニング
DK1904529T3 (da) * 2005-06-10 2010-11-15 Medical Res Council Anvendelse af Stefin A som et scaffoldprotein
WO2007009069A2 (en) * 2005-07-13 2007-01-18 Amgen Mountain View Inc. Heat lysis production of proteins
GB0601684D0 (en) * 2006-01-27 2006-03-08 Reckitt Benckiser Uk Ltd Composition, process for preparation and method of use
WO2007092465A2 (en) * 2006-02-07 2007-08-16 Dyao Pharmaceutical Corporation Topical delivery compositions
PT2061313E (pt) * 2006-09-16 2013-09-23 Soy Labs Llc Produtos e métodos que usam péptidos de soja para reduzir os níveis de colesterol total e de colesterol ldl
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
MX2009005733A (es) * 2006-12-18 2009-06-08 Danisco Us Inc Genencor Div Nuevas lacasas, composiciones y metodos de uso.
CA2673527A1 (en) 2006-12-21 2008-07-24 Danisco Us Inc. Compositions and uses for an alpha-amylase polypeptide of bacillus species 195
WO2008153934A2 (en) * 2007-06-06 2008-12-18 Danisco Us, Inc., Genencor Division Methods for improving protein performance
US20090048136A1 (en) * 2007-08-15 2009-02-19 Mcdonald Hugh C Kappa-carrageenase and kappa-carrageenase-containing compositions
WO2009058518A1 (en) * 2007-10-31 2009-05-07 Danisco Us Inc., Genencor Division Use and production of neutral metallproteases in a serine protease-free background
CA2704548A1 (en) * 2007-11-01 2009-05-07 Danisco Us Inc. Signal sequences and co-expressed chaperones for improving protein production in a host cell
GB0722332D0 (en) * 2007-11-14 2007-12-27 Reckitt Benckiser Uk Ltd Personal care article
WO2009096916A1 (en) * 2008-01-29 2009-08-06 Genencor International, Inc. Expression of streptomyces subtilisin inhibitor (ssi) proteins in bacillus and streptomyces sp.
CN101970634B (zh) 2008-02-04 2014-01-22 丹尼斯科美国公司 具有改变性质的TS23α-淀粉酶变体
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
WO2010044786A1 (en) 2008-10-15 2010-04-22 Danisco Us Inc., Genencor Division Modified variant bowman birk protease inhibitors
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
CN102341495A (zh) 2009-03-10 2012-02-01 丹尼斯科美国公司 巨大芽孢杆菌菌株DSM90相关的α-淀粉酶及其使用方法
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
US8877479B2 (en) 2009-04-08 2014-11-04 Danisco Us Inc. Halomonas strain WDG195-related alpha-amylases, and methods of use, thereof
WO2010123754A1 (en) 2009-04-24 2010-10-28 Danisco Us Inc. Proteases with modified pro regions
BRPI1009982A2 (pt) * 2009-05-01 2017-06-27 Signal Investment & Man Co composição antimicrobiana hidratante
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
GB0921001D0 (en) * 2009-11-30 2010-01-13 Aqua Bio Technology Asa Products and uses
DK3190183T3 (da) 2009-12-09 2019-10-14 Danisco Us Inc Sammensætninger og fremgangsmåder omfattende proteasevarianter
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
US20130023480A1 (en) * 2009-12-30 2013-01-24 Solae, Llc Purified Bowman-Birk Protease Inhibitor Proteins Isolated from a Soy Processing Sttream
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
SG184345A1 (en) * 2010-03-31 2012-11-29 Agency Science Tech & Res Amphiphilic linear peptide/peptoid and hydrogel comprising the same
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
PL2558573T3 (pl) 2010-04-15 2017-08-31 Danisco Us Inc. Kompozycje i sposoby obejmujące warianty proteazy
ES2625751T3 (es) 2010-05-06 2017-07-20 The Procter & Gamble Company Productos de consumo con variantes de proteasa
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
RU2718648C2 (ru) 2011-05-05 2020-04-10 ДАНИСКО ЮЭс ИНК. Композиции и способы, включающие варианты сериновой протеазы
WO2012151480A2 (en) 2011-05-05 2012-11-08 The Procter & Gamble Company Compositions and methods comprising serine protease variants
EP2751263A1 (de) 2011-08-31 2014-07-09 Danisco US Inc. Zusammensetzungen und verfahren mit einer variante eines lipolytischen enzyms
US20150017700A1 (en) 2011-12-22 2015-01-15 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
US9120841B2 (en) 2012-09-28 2015-09-01 Agency For Science, Technology And Research Amphiphilic linear peptidepeptoid and hydrogel comprising the same
CN117586986A (zh) 2012-10-12 2024-02-23 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
JP6858487B2 (ja) 2012-11-05 2021-04-14 ダニスコ・ユーエス・インク サーモリシンプロテアーゼ変異体を含む組成物及び方法
US20150344858A1 (en) 2012-12-19 2015-12-03 Danisco Us Inc. Novel mannanase, compositions and methods of use thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014194117A2 (en) 2013-05-29 2014-12-04 Danisco Us Inc. Novel metalloproteases
EP3004314B1 (de) 2013-05-29 2018-06-20 Danisco US Inc. Neuartige metalloproteasen
JP2016526880A (ja) 2013-05-29 2016-09-08 ダニスコ・ユーエス・インク 新規メタロプロテアーゼ
EP3260538B1 (de) 2013-05-29 2021-04-14 Danisco US Inc. Neuartige metalloproteasen
MX371497B (es) 2013-07-19 2020-01-31 Danisco Us Inc Composiciones y metodos que comprenden una variante de enzima lipolitica.
EP3044313B1 (de) 2013-09-12 2019-11-06 Danisco US Inc. Zusammensetzungen und verfahren mit protease varianten der lg12-klade
JP2016537965A (ja) * 2013-10-11 2016-12-08 ジェネンテック， インコーポレイテッド Ｎｓｐ４阻害剤及び使用方法
CN105813695A (zh) 2013-11-01 2016-07-27 斯弗尤姆生物制药有限公司 用于透皮递送治疗剂和美容剂的包含体
DK3514230T3 (da) 2013-12-13 2021-11-15 Danisco Us Inc Serinproteaser af bacillus-arter
DK3553173T3 (da) 2013-12-13 2021-08-23 Danisco Us Inc Serinproteaser af bacillus gibsonii-clade
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
WO2015143360A2 (en) 2014-03-21 2015-09-24 Danisco Us Inc. Serine proteases of bacillus species
WO2016061438A1 (en) 2014-10-17 2016-04-21 Danisco Us Inc. Serine proteases of bacillus species
EP3212662B1 (de) 2014-10-27 2020-04-08 Danisco US Inc. Serinproteasen
WO2016069557A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases of bacillus species
DK3212781T3 (da) 2014-10-27 2019-12-16 Danisco Us Inc Serinproteaser
EP3212783B1 (de) 2014-10-27 2024-06-26 Danisco US Inc. Serinproteasen
EP3550017B1 (de) 2014-10-27 2021-07-14 Danisco US Inc. Serinproteasen
US20180216090A1 (en) 2015-03-12 2018-08-02 Danisco Us Inc. Compositions and methods comprising lg12-clade protease variants
WO2016183509A1 (en) 2015-05-13 2016-11-17 Danisco Us Inc. AprL-CLADE PROTEASE VARIANTS AND USES THEREOF
WO2016205710A1 (en) 2015-06-17 2016-12-22 Danisco Us Inc. Proteases with modified propeptide regions
US11499146B2 (en) 2015-06-17 2022-11-15 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
CN107022432A (zh) * 2016-01-29 2017-08-08 高露洁-棕榄公司 清洁组合物
US20190136218A1 (en) 2016-05-05 2019-05-09 Danisco Us Inc Protease variants and uses thereof
MX2018014768A (es) 2016-05-31 2019-03-06 Danisco Us Inc Variantes de proteasa y sus usos.
EP4151726A1 (de) 2016-06-17 2023-03-22 Danisco US Inc Proteasevarianten und verwendungen davon
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018118917A1 (en) 2016-12-21 2018-06-28 Danisco Us Inc. Protease variants and uses thereof
US11946081B2 (en) 2016-12-21 2024-04-02 Danisco Us Inc. Bacillus gibsonii-clade serine proteases
US11298391B1 (en) * 2017-04-27 2022-04-12 Lorenol Laboratories, Inc. Topical skin health improvement compositions and administrations thereof
EP3717643A1 (de) 2017-11-29 2020-10-07 Danisco US Inc. Subtilisin-varianten mit verbesserter stabilität
WO2019245704A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
WO2019245705A1 (en) 2018-06-19 2019-12-26 Danisco Us Inc Subtilisin variants
EP3833731A1 (de) 2018-08-30 2021-06-16 Danisco US Inc. Zusammensetzungen mit einer lipolytischen enzymvariante und verfahren zur verwendung davon
US20230028935A1 (en) 2018-11-28 2023-01-26 Danisco Us Inc Subtilisin variants having improved stability
WO2020242858A1 (en) 2019-05-24 2020-12-03 Danisco Us Inc Subtilisin variants and methods of use
CN112062828B (zh) * 2019-06-10 2022-04-29 温州医科大学 Fgf-5多肽抑制剂及其生发应用
EP4090727A1 (de) 2020-01-13 2022-11-23 Danisco US Inc. Zusammensetzungen mit einer lipolytischen enzymvariante und verfahren zur verwendung davon
WO2022047149A1 (en) 2020-08-27 2022-03-03 Danisco Us Inc Enzymes and enzyme compositions for cleaning
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
CN117616120A (zh) 2021-06-30 2024-02-27 丹尼斯科美国公司 变体脂肪酶及其用途
CN117916354A (zh) 2021-09-03 2024-04-19 丹尼斯科美国公司 用于清洁的衣物洗涤组合物
WO2023114936A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023114795A1 (en) 2021-12-16 2023-06-22 The Procter & Gamble Company Automatic dishwashing composition comprising a protease
WO2023114939A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
CA3240638A1 (en) 2021-12-16 2023-06-22 Michelle Jackson Fabric and home care composition comprising a protease
WO2023114932A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Subtilisin variants and methods of use
WO2023168234A1 (en) 2022-03-01 2023-09-07 Danisco Us Inc. Enzymes and enzyme compositions for cleaning
WO2024050346A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Detergent compositions and methods related thereto
WO2024050343A1 (en) 2022-09-02 2024-03-07 Danisco Us Inc. Subtilisin variants and methods related thereto
WO2024102698A1 (en) 2022-11-09 2024-05-16 Danisco Us Inc. Subtilisin variants and methods of use

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
DE2437090A1 (de) * 1974-08-01 1976-02-19 Hoechst Ag Reinigungsmittel
JPS51125468A (en) * 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
US4152416A (en) * 1976-09-17 1979-05-01 Marra Dorothea C Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
FI69503C (fi) * 1984-03-13 1986-02-10 Neste Oy Ytbelagd bergsbehaollare eller tunnel
US5411873A (en) 1984-05-29 1995-05-02 Genencor, Inc. Process for producing heterologous polypeptides
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4999186A (en) * 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4937370A (en) * 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US5322770A (en) * 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1988002025A1 (en) * 1986-09-17 1988-03-24 Sri International Expression vectors for bacilli
US5087372A (en) * 1989-03-24 1992-02-11 Asahi Kasei Kogyo Kabushiki Kaisha Method for removing heavy metal ions from contaminated water and a porous membrane usable therefor
US5011681A (en) * 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073371A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5429950A (en) 1992-03-30 1995-07-04 Genencor International, Inc. Heterologous gene expression in bacillus subtilis: fusion approach
GB9415421D0 (en) 1994-07-30 1994-09-21 Procter & Gamble Cosmetic compositions and processes for manufacture thereof
AU709850B2 (en) 1994-11-28 1999-09-09 Procter & Gamble Company, The Topical skin care compositions containing thickened polyol carboxylic acid esters as skin conditioning agents
US6063611A (en) 1996-03-12 2000-05-16 Genencor International, Inc. Alkaline cellulase and method of producing same
WO1997038708A1 (en) * 1996-04-18 1997-10-23 The General Hospital Corporation Modulating epithelial-mesenchymal interactions
US5827508A (en) * 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
KR20000057166A (ko) 1996-11-22 2000-09-15 데이비드 엠 모이어 미용 조성물
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
HUP0102457A2 (hu) * 1998-07-20 2001-10-28 M & E Biotech A/S Új, biológiai ligandumok és célmolekulák azonosítására szolgáló eljárások
US5935556A (en) * 1998-07-30 1999-08-10 The Procter & Gamble Company Sunscreen compositions
US5989528A (en) 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
JP3855042B2 (ja) * 1998-09-22 2006-12-06 独立行政法人産業技術総合研究所 毛髪の鑑別法
US5972316A (en) * 1998-10-16 1999-10-26 The Procter & Gamble Company UV protection compositions
US5968485A (en) * 1998-10-16 1999-10-19 The Procter & Gamble Company UV protection compositions
AU1275599A (en) 1998-10-23 2000-05-15 Procter & Gamble Company, The Skin care compositions
GB9825854D0 (en) * 1998-11-25 1999-01-20 Univ Bristol Peptide
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Ｆｇｆ−５の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
WO2001072957A2 (en) * 2000-03-31 2001-10-04 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP4966470B2 (ja) * 2000-04-14 2012-07-04 ダニスコ・ユーエス・インコーポレーテッド 選択性標的化方法
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6822082B2 (en) * 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
US6537968B1 (en) 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
CN100580084C (zh) * 2000-12-13 2010-01-13 阿纳福公司 具有c型类凝集素结构域的支架结构的蛋白质组合文库
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AU2002339119A1 (en) * 2001-02-07 2002-12-03 Centre National De La Recherche Scientifique (Cnrs) Sequence of the photorhabdus luminescens strain tt01 genome and uses
CN100506984C (zh) * 2003-02-11 2009-07-01 巴斯德研究院 消旋酶的鉴别和鉴定、蛋白质特征的确定、及用于检测d－氨基酸和筛选能抑制消旋酶尤其是脯氨酸消旋酶活性的分子的测试
ATE486087T1 (de) * 2003-11-06 2010-11-15 Danisco Us Inc Fgf-5-bindende und geträgerte peptide
WO2005047302A1 (en) * 2003-11-06 2005-05-26 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7772181B2 (en) * 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US7803902B2 (en) * 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors

Also Published As

Publication number Publication date
WO2005046709A3 (en) 2005-11-24
WO2005047314A3 (en) 2006-04-20
WO2005046710A2 (en) 2005-05-26
JP2012024091A (ja) 2012-02-09
US7485618B2 (en) 2009-02-03
JP5728329B2 (ja) 2015-06-03
DK1680507T3 (da) 2011-10-10
US20110230405A1 (en) 2011-09-22
JP2008500805A (ja) 2008-01-17
CA2544820C (en) 2014-02-18
WO2005047511A3 (en) 2005-11-24
US20050203026A1 (en) 2005-09-15
ATE486087T1 (de) 2010-11-15
US20080113917A1 (en) 2008-05-15
ATE482972T1 (de) 2010-10-15
US20050238607A1 (en) 2005-10-27
US7413877B2 (en) 2008-08-19
WO2005046710A3 (en) 2005-11-24
WO2005047314A2 (en) 2005-05-26
EP1692159A2 (de) 2006-08-23
US7524816B2 (en) 2009-04-28
EP1680507A2 (de) 2006-07-19
WO2005046709A2 (en) 2005-05-26
DE602004029812D1 (de) 2010-12-09
CA2544820A1 (en) 2005-05-26
WO2005047511A2 (en) 2005-05-26
US20090111160A1 (en) 2009-04-30
US20080269139A1 (en) 2008-10-30
EP1692158B1 (de) 2011-10-26
DK1692158T3 (da) 2012-02-06
EP1680507B1 (de) 2011-06-22
ATE530560T1 (de) 2011-11-15
US20050202535A1 (en) 2005-09-15
ATE513917T1 (de) 2011-07-15
EP1692158A2 (de) 2006-08-23
EP1692160A2 (de) 2006-08-23
EP1692160B1 (de) 2010-10-27
JP4843497B2 (ja) 2011-12-21
ES2375360T3 (es) 2012-02-29
US20130065829A1 (en) 2013-03-14
US7696173B2 (en) 2010-04-13
EP1692159B1 (de) 2010-09-29

Similar Documents

Publication Publication Date Title
ATE482972T1 (de) Tgf-beta1-bindende und geträgerte peptide
WO2006121610A3 (en) Personal care compositions and methods for their use
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
ATE542920T1 (de) Modifiziertes menschliches wachstumshormon
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
DE602004011770D1 (de) Fusionsproteine
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
ATE424842T1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
DK1534830T3 (da) In vito-peptid-ekspressionsbibliotek
CY1112267T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
ATE363531T1 (de) Claudin polypeptide
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
DE602004015142D1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften